Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
Journal of Oncology Practice · 2018-01 · 14 (1) · e1-e10
DOI: 10.1200/jop.2017.025288 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Oncology Practice, 2018-01. Verfasst von Narjust Duma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, MN; and Rutgers University-New Jersey Medical School, Newark, NJ. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit wurde bisher 395-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Purpose
Many cancer clinical trials lack appropriate representation of specific patient populations, limiting their generalizability. Therefore, we determined the representation of ethnic minorities and women in cancer clinical trials.
Methods
Enrollment data from all therapeutic trials reported as completed in ClinicalTrials.gov from 2003 to 2016 were analyzed. We calculated enrollment fractions (EFs) for each group, defined as the number of enrollees divided by the 2013 Surveillance, Epidemiology, and End Results (SEER) database cancer prevalence.
Results
Of 1,012 clinical trials, 310 (31%) reported ethnicity with a total of 55,689 enrollees. Participation varied significantly across ethnic groups. Non-Hispanic whites were more likely to be enrolled in clinical trials (EF, 1.2%) than African Americans (EF, 0.7%; P < .001) and Hispanics (EF, 0.4%; P < .001). A decrease in African American (6% v 9.2%) and Hispanic (2.6% v 3.1%) enrollment was observed when compared with historical data from 1996 to 2002. Younger patients (age younger than 65 years) were more likely to be enrolled in clinical trials than the elderly (64% v 36%; P < .001). Low recruitment of female patients was observed in clinical trials for melanoma (35%), lung cancer (39%), and pancreatic cancer (40%).
Conclusion
We observed a decrease in recruitment of minorities over the past 14 years compared with historical data. African Americans, Hispanics, and women were less likely to be enrolled in cancer clinical trials. Future trials should take extra measures to recruit participants that adequately represent the US cancer population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Mayo Clinic, Rochester, MN; and Rutgers University-New Jersey Medical School, Newark, NJ.
Zitieren
APA
Duma, N., Vera Aguilera, J., Paludo, J., Haddox, C. L., Gonzalez Velez, M., Wang, Y., Leventakos, K., Hubbard, J. M., Mansfield, A. S., Go, R. S., & Adjei, A. A. (2018). Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. Journal of Oncology Practice, 14(1), e1-e10. https://doi.org/10.1200/jop.2017.025288
Vancouver
Duma N, Vera Aguilera J, Paludo J, Haddox CL, Gonzalez Velez M, Wang Y, et al. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. Journal of Oncology Practice. 2018;14(1):e1-e10. doi:10.1200/jop.2017.025288
BibTeX
@article{Duma2018,
author = {Duma, Narjust and Vera Aguilera, Jesus and Paludo, Jonas and Haddox, Candace L and Gonzalez Velez, Miguel and Wang, Yucai and Leventakos, Konstantinos and Hubbard, Joleen M and Mansfield, Aaron S and Go, Ronald S and Adjei, Alex A},
title = {Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years},
journal = {Journal of Oncology Practice},
year = {2018},
volume = {14},
number = {1},
pages = {e1--e10},
doi = {10.1200/jop.2017.025288}
}
EUVIMED